Journal article

Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection

EJ Bartlett, VS Cull, NL Brekalo, JC Lenzo, CM James

Immunology & Cell Biology | WILEY | Published : 2002


Delivery of type I IFN transgenes by naked DNA immunization can protect against cytomegalovirus infection and myocarditis. Here, we investigate IFN transgene expression, antiviral efficacy, and immunomodulation of myocarditis using various treatment regimes in a mouse CMV model. In vivo expression of the IFN transgene was observed in the sera for 35 days post-DNA inoculation. Prophylactic IFN-A6 and IFN-B DNA treatment for 14 days prior to murine cytomegalovirus (MCMV) infection was more efficacious in significantly reducing viral titres, than 2 days prior to or 2 days post-virus infection. Similarly, IFN-A6 DNA treatment commencing 14 days prior to virus infection was superior in suppressin..

View full abstract

University of Melbourne Researchers